Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F22%3A00083436" target="_blank" >RIV/00023001:_____/22:00083436 - isvavai.cz</a>
Result on the web
<a href="https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435" target="_blank" >https://reader.elsevier.com/reader/sd/pii/S1053249822019568?token=4B62134E6FABC4AE7CF7E7185B6B3A1E6BEA268D980B19E25EFCDA740DFCB424B71A2C203AA9ECBE254844D9519C1FC7&originRegion=eu-west-1&originCreation=20221206151435</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.healun.2022.05.017" target="_blank" >10.1016/j.healun.2022.05.017</a>
Alternative languages
Result language
angličtina
Original language name
Intermediate-dose prophylactic anticoagulation with low molecular weight heparin is safe after bioprosthetic artificial heart implantation
Original language description
Antithrombotic therapy is mandatory in standard mechanical circulatory support, usually a vitamin K antagonist and/or antiplatelet agent is used. The autoregulated Aeson total artificial heart (A-TAH, Carmat SA, Vélizy-Villacoublay, France) is designed to replace the heart in patients with end-stage heart failure. For the European pivotal study, heparin and/or LMWH was proposed with a low antiXa target starting during the first post implant days. Fifteen (n = 15) male patients were implanted between September 2016 and December 2020. Intermediate dose LMWH anticoagulation was finally used in 12 patients with a median introduction time of 29.5 (range 8-152) days after A-TAH implantation. The results suggest that an intermediate-dose prophylactic anticoagulation with LMWH is feasible with no evidence of an increase in thrombotic complications or coagulation activation in patients implanted with the autoregulated A-TAH.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of heart and lung transplantation
ISSN
1053-2498
e-ISSN
1557-3117
Volume of the periodical
41
Issue of the periodical within the volume
9
Country of publishing house
US - UNITED STATES
Number of pages
4
Pages from-to
1214-1217
UT code for WoS article
000890162000007
EID of the result in the Scopus database
2-s2.0-85132800172